Unigene Laboratories, Inc. reported the issue of its first patent for its Site-Directed Bone Growth (SDBG). The technology is designed to facilitate and accelerate bone growth at targeted locations using a minimally invasive procedure that can be performed on an outpatient basis. Animal studies have shown that SDBG can grow significant amounts of high quality bone.

U.S patent #7, 531, 518, “Method of Fostering Bone Formation and Preservation,” claims to provide broad protection for the inducement of rapid bone growth and its subsequent preservation using a variety of therapeutic agents, including parathyroid hormone, calcitonin and bisphosphonates. The U.S. Patent and Trademark Office are currently reviewing several other patent applications relative to the SDBG program.

“The issuance of this first patent provides us with broad intellectual property protection for this novel technology,” stated Dr. Warren Levy, President and CEO of Unigene. “This patent and the potential issuance of other patent applications could provide Unigene with a comprehensive family of patents that would cover a variety of bone ailments that affect a large segment of the population.”

He added, “Although still in the early stages of development, SDBG may ultimately allow surgeons to stimulate rapid bone growth in patients with low bone density in areas such as the hip or spine. In addition, SDBG may ultimately be used to accelerate the rate of fracture healing. We believe that potential future applications may include the treatment or prevention of hip and vertebral fractures, the replacement of current vertebroplasty techniques, the stabilization of prosthetic devices, and the repair of long bone fractures.”